NCT01806974 Consequences of Anti-interleukin 6 Immunotherapy Treatment for Rheumatoid Arthritis on Periodontium Status TERMINATED Phase PHASE4
NCT01793519 Stopping TNF Alpha Inhibitors in Rheumatoid Arthritis Status ACTIVE_NOT_RECRUITING Phase PHASE4
NCT01793259 Preference Methotrexate (MTX) Pre-filled Syringe Versus Pre-filled Pen in Rheumatoid Arthritis (RA) Status COMPLETED Phase PHASE3
NCT01793103 Brigham and Women's Rheumatoid Arthritis Sequential Study Status ACTIVE_NOT_RECRUITING Phase N/A
NCT01791738 Acetabular Shell Positioning Using Patient Specific Instruments Status COMPLETED Phase PHASE1
NCT01791205 ARMONIA: An Observational Study of Biologic Drugs in Monotherapy or Combination With DMARDs in Italian Clinical Practice and the Efficacy and Safety of RoActemra/Actemra (Tocilizumab) Monotherapy in Patients With Rheumatoid Arthritis Status COMPLETED Phase N/A
NCT01783730 Assessment of the Safety of Adalimumab in Rheumatoid Arthritis Patients Showing Rapid Progression of Structural Damage of the Joints, Who Have no Prior History of Treatment With Disease-modifying Anti-rheumatic Drugs or Biological Agents Status COMPLETED Phase N/A
NCT01783015 Study of Etanercept in Subjects With Rheumatoid Arthritis Who Have Had an Inadequate Response to Adalimumab or Infliximab Plus Methotrexate Status TERMINATED Phase PHASE4
NCT01782469 Rheumatoid Arthritis Patients on Adalimumab to Evaluate Its Effect on Synovitis Using Ultrasonography in an Egyptian Population Status TERMINATED Phase N/A
NCT01781702 Phase 3 Study of Pelubiprofen Tab. & Celebrex Cap. in Rheumatoid Arthritis Patients Status COMPLETED Phase PHASE3
NCT01776034 Health Promotion and Wellness Program for Adults With Disabling Conditions Status COMPLETED Phase NA
NCT01774877 A Clinical Study of Xin'an Medicine in the Treatment of Bi Syndrome Status COMPLETED Phase NA
NCT01772316 A Long-Term Extension Study of WA22763 and NA25220 of Subcutaneous RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis Status COMPLETED Phase PHASE3